논문투고규정

I. AIMS AND SCOPE

The Korean Journal of Adult Nursing (KJAN) is the official peer-reviewed research journal of the Korean Society of Adult Nursing (KSAN). KJAN is devoted to the dissemina- tion of groundbreaking research on theory, practice, and education in the field of adult nursing. Research on other subject areas or issues that contribute to adult nursing is published at the discretion of the Editorial Board. The goal of KJAN is to contribute to health maintenance, health pro- motion, and disease prevention and management in adults by publishing research. KJAN is published four times per year at the end of February, May, August, and November.

II. RESEARCH & PUBLICATION ETHICS

1. Research Ethics

For policies on research and publication ethics that are not stated in these instructions, the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors (ICMJE) or the Committee on Publication Ethics (COPE) guidance (https://publicatio-nethics.org/guidance) can be applied. Further, all process- es of handling research and publication misconduct shall follow the applicable COPE flowchart.

Statements of human and animal rights: Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Subjects, outlined in the Declaration of Helsinki (https://www.wma.net/poli-cies-post/wma-declaration-of-helsinki-ethical-princi-ples-for-medical-research-involving-human-subjects/). Any study involving human subjects or human data must be reviewed and approved by a responsible institutional review board (IRB). Research involving meta-analyses, sys- tematic reviews, and literature reviews does not require IRB review. For secondary data analyses, IRB review and approval for an exempt study may be required based on the decision of the Editorial Board. When necessary, the Editorial Board may request any documentation regarding ethical issues of the manuscript such as written consent or the approval of the study by the IRB. Furthermore, for stud- ies involving human subjects, the authors must explicitly state in the paper that the research received IRB approval and was conducted in accordance with the relevant stan- dards.
Statement of informed consent: Copies of written informed consent and IRB approval for clinical research should be kept. If necessary, the editor or reviewers may request cop- ies of these documents to resolve questions about IRB ap- proval and study conduct.
Originality and duplicate publication:Duplicate publica- tion or duplicate submission is prohibited in accordance with the ICMJE recommendations (https://www.icmje. org/recommendations/browse/publishing-and-editori-al-issues/overlapping-publications.html). Manuscripts that have been published or are being submitted to other journal(s) should not be submitted to KJAN. Manuscripts that have been published or are currently under consider- ation for publication in KJAN must not be submitted to an- other journal. The corresponding author must obtain ap- proval from the Editors-in-Chief of both related journals if the author wants to reprint a published manuscript in an- other language.

If manuscripts have been submitted or are currently un- der consideration for publication in KJAN, the Editorial Board will determine the nature and degree of duplicate publication or duplicate submission for the manuscript. If a manuscript has been published in KJAN, the KSAN ethics committee will determine the nature and degree of dupli- cation.

2. Authorship

KJAN follows the recommendations for authorship set out by the ICMJE Authorship guidelines (http://www.icmje.org/icmje-recommendations.pdf ). Authorship is attributed only to individuals who have directly participated and made significant contributions to the creation of the man- uscript. Authorship should be based upon all four of the following criteria: 1) substantial contribution to the con- cept or design of the work, or the acquisition or analysis and interpretation of data; 2) drafting the work or revising it critically for important intellectual content; 3) final ap- proval of the version submitted for publication; 4) account- ability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All other con- tributors not listed as authors should be mentioned in the acknowledgements section.
If a manuscript is based on a master’s thesis or doctoral dissertation, the author must disclose that the manuscript is the product of his/her thesis or a dissertation for an aca- demic degree. The first author must be the recipient of the academic degree from the work presented in the manu- script.
Any changes in authorship (addition, deletion or change in order of authorship) must be approved by the Editorial Board prior to the manuscript’s acceptance for publication. To request such a change, the Editor must receive the fol- lowing from the corresponding author: (a) the reason(s) for the change in the author list; and (b) written confirmation (e-mail, letter) from all authors that they agree with any ad- dition, removal, or rearrangement.

3. Conflicts of Interest

The corresponding author will be responsible for inform- ing the editor regarding potential conflicts of interest for all listed authors that might influence their interpretation of data. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there is no conflict of inter- est, this should also be explicitly stated as “The author(s) declared no conflict of interest.”

4. Registration of a Clinical Trial

This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Require- ment of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). All clinical trials (as defined by the ICMJE) must be registered in a publicly accessible trial registry. For all other types of studies, including systematic reviews, prospective registra- tion is strongly encouraged. If a study has been registered, please cite the registration number in both the abstract and body of the paper. The journal accepts registration in any of the primary registries that participate in the World Health Organization International Clinical Trials Portal (http://http://www.clinicaltrials.gov/), Internation- al Standard Randomized Controlled Trial Number Registry (https://www.isrctn.com/), or the Clinical Research Infor- mation Service, Korea Disease Control and Prevention Agency (KDCA) (https://cris.nih.go.kr/cris/index/index. do).

5. Research Data Sharing and Transparency

This journal encourages and enables authors to share data that supports the research publication, where ap- propriate, and to interlink the data with other published articles. Research data refers to the results of observa- tions or experiments that validate the research findings. To facilitate reproducibility and data reuse, this journal encourages authors to share their software, codes, models, algorithms, protocols, methods, and other useful materials related to the project. Data generated through the partici- pation of subjects and the public should be put to maxi- mum use by the research community and, whenever possi- ble, translated to deliver patient benefits. Data sharing benefits numerous research-related activities: reproducing analyses, testing secondary hypotheses, developing and evaluating novel statistical methods, teaching, aiding the design of future trials and meta-analyses, and helping to prevent error, fraud, and selective reporting. To promote more transparent and reproducible research, we ask au- thors to submit a Data Availability Statement in the manu- script to help readers understand how they can access the data, code, and other resources that support the research findings.

The following are examples of data-sharing statements:

1. • Example 1: The data can be obtained from the corre- sponding authors.
2. • Example 2: The data can be obtained from the Supple- mentary Material.
3. • Example 3: (In the case of healthcare big data) The data can be obtained from (the name of the)_repository source.
4. • Example 4: No new data were created or analyzed during this study. Data sharing is not applicable to this article.

6. Artificial Intelligence (AI)–Assisted Technologies

At submission, authors are required to disclose whether they used AI-assisted technologies (such as Large Lan- guage Models [LLMs], chatbots, or image creators) in their work. Authors should describe how they used AI-assisted technologies in both the cover letter and the appropriate section of the manuscript. For example, if AI was used for writing assistance, this should be described in the Ac- knowledgments section. If AI was used for data collection, analysis, or figure generation, the authors should describe this use in the Methods section. Chatbots (such as ChatGPT) should not be listed as authors because they cannot be held responsible for the accuracy, integrity, and originality of the work, and these responsibilities are re- quired for authorship. Therefore, authors are responsible for any submitted material that included the use of AI-as- sisted technologies. Authors should carefully review and edit AI-generated results because AI can generate authori- tative-sounding output that can be incorrect, incomplete, or biased. Authors must ensure there is appropriate attri- bution of all quoted material, including full citations, and should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author.

7. Process for Managing Publication Malpractice

If reviewers or readers suspect publication malpractice, such as fabrication, falsification, salami slicing, plagiarism, or simultaneous/ duplicate publication, inappropriate changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the process of resolution will be initiated following the flowchart provided by the COPE

guidance (https://publicationethics.org/guidance).
If a published manuscript is suspected of an ethics viola- tion, the KSAN ethics committee, which includes the Edi- tor-in-Chief of KJAN, will be convened. The procedure will be conducted in the following order: a preliminary investi- gation, a second investigation, and decision, in accordance with the prescribed regulations. If a published manuscript is determined to involve an ethics violation, members found to have violated this regulation and the general ethi- cal principles of research will be subject to the following consequences, and other relevant matters shall be deter- mined by the KSAN ethics committee.

1. The published manuscript will be retracted, and a public statement will be made regarding the reason for retraction.
2. Submission privileges to KJAN will be suspended for three years.
3. The retraction of the manuscript will be announced on KJAN’s official website and in the printed journal.

III. GUIDELINES FOR MANUSCRIPT PREPARATION

1. Types of Manuscripts

KJAN publishes original articles, review articles, invited ar- ticles, and editorials.

1. Original Articles include full papers reporting original research. These are reports of empirical findings from high-quality basic and clinical research studies within the scope and focus of KJAN.
2. Review Articles include critical presentations of topics relevant to nursing theory, practice, and education re- garding adult nursing. Unsolicited reviews will be con- sidered for publication if topical, of high quality, and subject to peer review. The body of a review article should be a comprehensive, scholarly evidence-based review of the literature, accompanied by a critical analysis and reasonable conclusions.
3. Invited Articlesprovide concise reviews of a subject of importance to nursing researchers written by an invit- ed expert in nursing science.
4. Editorials are commissioned by editors, and may in- clude comments on manuscripts included, recent re- search trends in the field of adult nursing, and opin- ions on relevant topics.

2. General Guidelines

1. Language and style: Manuscripts should be written in English. The paper size setting should be A4, and the file should be compatible with Microsoft Word. The format- ting requirements are as follows: the texts should be double-spaced and in Times New Roman 12-point font size with margins of top 30 mm, bottom 25 mm, left 25 mm, and right 25 mm. Page numbers are placed at the bottom of each page.
2. Manuscript length: The manuscript has different limits depending on the type of article submitted. (1) An origi- nal article should be no more than 6,000 words; (2) A re- view article should not exceed 8,000 words; and (3) An editorial should be no longer than 2,500 words. This word count includes only the main body of the text (i.e., not abstract, references, tables, or figures).
3. Abbreviations: Do not use abbreviations in the title or abstract and limit their use in the text. Expand all abbre- viations at first mention in the text. Avoid using abbrevi- ations in the article title. For standard abbreviated words and units, refer to the NLM (National Library of Medi- cine) Style Guide for Authors, Editors, and Publishers, 2nd Edition (2007) (http://www.nlm.nih.gov/citingmed- icine).
4. Description of participants: Authors should ensure cor- rect use of the terms sex (when reporting biological fac- tors) and gender (identity, psychosocial or cultural fac- tors), and, unless inappropriate, report the sex or gender of study participants, the sex of animals or cells, and de- scribe the methods used to determine sex or gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance.
5. Permissions: Authors should obtain permission from the copyright owners to use measurements or instru- ments for their studies. Permission to reproduce previ- ously published material must also be obtained in writ- ing from the copyright holder (usually the publisher) and acknowledged in the manuscript.
6. Describing machinery or technical equipment: Gener- ic names should be used. When proprietary brands are used in research, include the name of the brand and the manufacturer, city (state), and nation in parentheses af- ter the first mention of the generic name in the Methods section. Brand names are identified by symbols such as TM and ®, and should only be used when necessary.
7. References and citation style: References and citations follow the National Library of Medicine (NLM) Style. The submitting authors are responsible for ensuring ad- herence to NLM guidelines.

3. Research Reporting Guidelines

Authors are encouraged to adhere to relevant reporting guidelines when describing their study. Reporting guide- lines endorsed by the journal are listed below, from the EQUATOR network (https://www.equator-network.org/).

Observationalcohort,case-control,andcross-sectionalstudies Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Qualitative studies
Consolidated Criteria for Reporting Qualitative Research (COREQ)
Standards for Reporting Qualitative Research (SRQR)
Quasi-experimental/ non-randomized trials
Transparent Reporting of Evaluations with Non-random- ized Designs (TREND)
Randomized (and quasi randomized) controlled trials Consolidated Standards of Reporting Trials (CONSORT) Study of Diagnostic accuracy/assessment scale
Standards for the Reporting of Diagnostic Accuracy Studies (STARD)
SystematicReviewandmeta-analysis
Preferred Reporting Items for Systematic Reviews and Me- ta-analyses (PRISMA)
Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Qualityimprovementstudies
Standards for Quality Improvement Reporting Excellence (SQUIRE)

4. Manuscript Components

The composition of manuscripts shall be in the following order: title page, abstract and keywords, main text, refer- ences, tables and figures, and appendices. Each section be- gins on a new page. The main body of the manuscript (in- cluding the references, figures, tables, acknowledgements, and any funding information) should not include any iden- tifying information, such as the authors’ names or affilia- tions, to ensure a blind review.

1. Title page

   The following should be included on the title page: (1) the title of the article; (2) the running title; (3) author in- formation (ORCID number is required for all authors);
   (4) permission for measurements/instruments used in the study; (5) IRB approval institution and number; (6) disclosure; and (7) reporting guidelines checklist rele- vant to the research design used.

2. Abstract and Keywords

   An abstract of up to 250 words for articles (including re- views) should be typed double-spaced on a separate page. It should cover the main factual points, including statements of the Purpose, Methods, Results, and Con- clusion. The abstract should be accompanied by a list of three to five keywords for indexing purposes. Medical Subject Headings (MeSH) keywords (http://www.nlm.nih.gov/ mesh/meshhome.html) should be used, with careful selection of keywords that precisely reflect the focus of the study.

3. Main text

   The text should be composed in the following order: In- troduction, Methods, Results, Discussion, Conclusion, and References.

   Introduction:Clearly state the need for this study and the main question or hypothesis of the study. Summa- rize the literature review or background in the area of the study.

   Methods:Describe the study design, setting and sam- ples, measurements/instruments, data collection/pro- cedure, ethical considerations, and data analysis. If a study presents qualitative research, the instrument can be omitted. When discussing research methods, it is important to provide specific and detailed information to enable reproducibility. In the section on ethical consid- erations, the author should state that the study protocol was approved by the institutional review board (IRB No. ##-##-###). Please provide the initials of institutional names at the time of submission for peer review.

   Results:Describe the main results in a concise para- graph. This section should be the most descriptive.

   Discussion:The discussion should be based only on the reported results. It is strongly recommended that au- thors discuss how the study findings relate to advances in nursing practice, nursing knowledge development, and nursing implications.

   Conclusion:State the conclusions and recommenda- tions for further study. Do not summarize the study re- sults.

4. References

   In-text Citation: Citations of references in the text should follow Citing Medicine: The NLM Style Guide for Authors Editors, and Publishers 2nd edition (http:// www.nlm.nih.gov/citingmedicine). References should be numbered serially in the order of appearance in the text, with numbers in brackets [ ] (e.g., social support [1], fatigue [2,3], depression [4-6]). If a reference is cited more than once, use the original reference number (e.g., social support [1,2], fatigue [2-5], depression [1,4-6]).

   Reference list: References should be listed on a separate page at the end of the paper in the order of citation. The number of references should be 35 or less for an original article except for a manuscript on model construction, which is allowed to include up to 50 references. Cita- tions of master’s and doctoral dissertations should be minimized, with a maximum of three citations.

5. Tables and Figures

   There should be no more than five tables and figures in total. Tables and figures should be self-contained and complement, but not duplicate, information contained in the text. Each table and figure should be placed on a separate page. All lines are to be single. Vertical lines are not acceptable. The title of a table should be placed on top. Within the title, the first letters of important words should be capitalized (e.g., Table 1. Clinical Characteris- tics of the Sample). The title of the figure should be placed below the figure with the first letter capitalized (e.g., Figure 1. Path diagram of the model.). Tables and Figures should be numbered consecutively in Arabic numerals. All abbreviations used in tables should be ex- plained in footnotes. List abbreviations in alphabetical order; do not include the word “and” before the last ab- breviation (e.g., BP =blood pressure; ED =emergency department). Footnote symbols including asterisks and other symbols should be placed after abbreviations in the table. Table footnotes should be indicated with su- perscript symbols in sequence: †, ‡, §, ǁ, ¶, #, *, ††
   If the point value of a number can exceed 1, write “0”
   before the decimal point (e.g., t= 0.26, F= 0.98, R2 = .61), otherwise do not write “0” before the decimal point (e.g., p < .001). The p value (as an indicator of statistical signif- icance) should be written without a footnote and should be rounded to three decimal places (e.g., p = .003). If “p” is .000, then indicate that pis less than 0.001 (e.g., p < .001). Percentages (%) should be rounded off to one decimal place (e.g., 24.7%); test statistics, such as t, F, x2, and r, should be rounded off to two decimal places (e.g., t= 0.26, F= 0.98, R2 = .61).

6. Appendices

   Authors should submit an appendix containing the final developed instrument in instrument development stud- ies and a list of reviewed articles in a systematic review or meta-analysis.

5. Reference Format

1. Journals
   1. For six or fewer authors, list all authors:

      1. Han S, Min J, Kim DK, Kong ID, Kim N. The under- standing and application of telomere length as an emerging biomarker in adult nursing research: a re- view. Korean J Adult Nurs. 2023;35(1):1-12. https:// doi.org/10.7475/kjan.2023.35.1.1

   2. For more than six authors, list the first six followed by et al.

      1. Lee S, Kim MK, Hong EY, Lee JJ, Kim HJ, Kim HS, et al. Structural equation modeling on spiritual nurs- ing care of clinical nurses based on the theory of planned behavior. Korean J Adult Nurs. 2022;34(1): 27-38. https://doi.org/10.7475/kjan.2022.34.1.27

   3. Forthcoming journal articles

      1. van Corven CT, Bielderman A, Wijnen M, Leontje- vas R, Lucassen PL, Graff MJ, et al. Defining empow- erment for older people living with dementia from multiple perspectives: a qualitative study. Int J Nurs Stud. Forthcoming 2020 Nov 10. https://doi.org/ 10.1016/j.ijnurstu.2020.103823

2. Periodicals or magazines

   1. Rutan C. Creating healthy habits in children. Parish Nurse Newsletter. 2012 May 15:5-6.

3. Newspaper articles

   1. Cho CU. Stem cell windpipe gives Korean toddler new life. The Korea Herald. 2013 May 1; Sect. 01.

4. Books
   1. Reference to an entire book
      1. Hughes JH. Military veteran psychological health and social care: contemporary issues. 1st ed. Lon- don: Taylor & Francis; 2017.
      2. Kim SJ. Nursing theory. Seoul: Soomoonsa; 1985.
   2. Chapter in an edited book

      1. Miller CW. Applied cardiovascular physiology. In: Wingfield WE, Raffe MR, editors. The veterinary ICU book. Jackson, WY: Teton NewMedia; 2002. p. 1-14.

   3. An edited book

      1. Munslow A, Rosenstone RA, editors. Experiments in rethinking history. New York, NY: Routledge; 2004.

   4. Unknown authors or editors

      1. Merriam-Webster’s collegiate dictionary. 10th ed. Springfield, MA: Merriam-Webster; 1995.

   5. Book with translator(s)

      1. McEwen M, Wills EM. Theoretical basis for nursing. 4th ed. Koh CK, translator. Philadelphia, PA: Wolters Kluwer; 2019. p. 20-5.

   6. An encyclopedia or dictionary
      1. Sadie S, editor. The New Grove dictionary of music and musicians. 6th ed. London: Macmillan; 1980.
      2. Fitzpatrick JJ, Wallace M, editors. Encyclopedia of nursing research. 3rd ed. New York, NY: Springer Publishing Company; 2012.
5. Scientific and technical reports

   1. Hong S, Sung M, Choi J, Kim J, Kim S. Family poli- cies implications in the context of an increase in one-person households. Korean Women’s Development Institute Report. Seoul: Korean Women’s Development Institute; 2017 July. Report No.: 1105012716.

6. Unpublished dissertations and theses: Not recom- mended. Maximally three dissertations and theses in total are al- lowed if necessary.
   1. Dissertations

      1. Zhao JJ. Design of a 3D virtual learning environment for acquisition of cultural competence in nursing education: experience of nursing and other health care students, instructors, and instructional design- ers [dissertation]. Vancouver: University of British Columbia; 2019. p. 100-5.

   2. Theses

      1. Huh MS. Effect of Danjeon breathing on stress uri- nary incontinence and quality of life in middle aged wom- en [master’s thesis]. Busan: Dongeui Univer- sity; 2005.

7. Conference proceedings
   1. Unpublished proceedings

      1. Lankntree C, Briere J. Early data on the trauma symp- tom checklist for children (TSCC). Paper pre- sented at: The meeting of the American Professional Society on the Abuse of Children; 1991 January 25; San Diego, CA.

   2. Posters

      1. Cho YJ, Han YR. The relationship between the pro- fessional self concept, work stresses and their triage competency in emergency nurses. Poster session pre- sented at: Korean Society of Nursing Science; 2020 October 23; Seoul.

8. Web

   1. Ministry of the Interior and Safety. Safety experience center [Internet]. Sejong: Ministry of the Interior and Safety; 2022 [cited 2023 January 12]. Available from: https://www.mois.go.kr/frt/sub/a06/b10/safe- tyExperience/screen.do

IV. SUBMISSION AND PEER REVIEW

1. Submission

Manuscripts should be submitted electronically via this journal’s submission system (https://submit.kjan.or.kr/).

The first and corresponding authors should be members of KSAN, with the exception of non-Korean authors. Under certain circumstances, non-members can submit manu- scripts following approval by the Editorial Board. All corre- spondence, including notification of the editor’s decision and requests for revisions, will be processed via this sys- tem. Authors should complete the Submission Checklist and sign the Copyright Transfer Agreement form and sub- mit via the submission system. For any questions regarding the use of the online system, please contact the KJAN pub- lication director via phone, fax, or e-mail.

2. Peer Review

This journal follows a double-blind peer review process. Each submission will initially be assessed by the editors to determine suitability for publication in this journal. If a submission is deemed suitable, it will typically be sent to a minimum of three reviewers for an independent expert as- sessment of the scientific quality. The decision as to wheth- er an article is accepted or rejected will be taken by our ed- itors.

1. Preview: The editorial committee initially assesses each submission. The primary goal is to quickly determine which papers should not be sent for peer review and which ones should. To prevent delays for authors who may wish to submit their work elsewhere, papers that do not meet basic standards or are unlikely to be published, even with a favorable peer review—such as those with insufficient novel contributions or unclear relevance to the field—may be rejected at this stage.
2. Peer-review process: There is a two-week peer review period, and the first decision is made after the evalua- tion is finished. Following the review, the Editorial Board will decide between the options: acceptable options in- clude minor revision, major revision, or rejection. The Editorial Board may request authors to make changes to the manuscript in response to reviewers’ comments. If the author deems a reviewer’s opinion to be unaccept- able or thinks that a reviewer has misinterpreted the data, a reasonable explanation should be provided. Au- thors should try their best to comply with any requests made by the reviewers to modify the manuscript.
   After making changes to the manuscript, the author should upload the updated files along with a response to each reviewer’s comment. Revisions from the author must be finished within 14 days of the request. The Edi- torial Board will inform the author if it is not received by the deadline. The author should discuss an extension with the Editorial Board if they want to prolong the revi- sion window past 14 days. The Editorial Board may con- sider further review upon the author’s request. The Edi- torial Board will ultimately decide whether to approve the submitted manuscript for publication and may, if necessary, ask for additional alterations, edits, and dele- tions to the article text. Statistical editing is also done if a statistician needs to review the data professionally.
   The Editor-in-Chief of KJAN will make the final decision regarding the manuscript’s publication based on the re- viewers’ comments and the scientific merits of the man- uscript. Any potential or existing conflict and issues in the manuscript must be discussed in detail with the Edi- torial Board.
3. Appeals of decisions: Any appeals against the editorial decision must be made within 2 weeks of the date of the decision letter. Authors who wish to appeal against a de- cision should contact the Editor-in-Chief, explaining in detail the reasons for the appeal. All appeals will be dis- cussed with at least one other associate editor. If consen- sus cannot be reached thereby, an appeal will be dis- cussed at a full editorial meeting. The process of handling complaints and appeals follows the COPE guidance (https://publicationethics.org/guidance). KJAN does not consider second appeals.

V. FINAL PREPARATION FOR PUBLICATION

1. Final Version

After the paper has been accepted for publication, the au- thor(s) should submit the final version of the manuscript. The names and affiliations of the authors should be dou- ble-checked, and if the originally submitted image files were of poor resolution, higher-resolution image files should be submitted at this time. Symbols (e.g., circles, tri- angles, squares), letters (e.g., words, abbreviations), and numbers should be large enough to be legible on reduction to the journal’s column widths. All symbols must be de- fined in the figure caption. If references, tables, or figures are moved, added, or deleted during the revision process, renumber them to reflect such changes so that all tables, references, and figures are cited in numeric order.

2. Manuscript Corrections

Before publication, the manuscript editor will correct the manuscript so that it meets the standard publication for- mat. The author(s) must respond within 48 hours when the manuscript editor contacts the corresponding author for revisions. If the response is delayed, the manuscript’s pub- lication may be postponed to the next issue.

3. Proofs and Reprints

The author(s) will receive the final version of the manu- script as a PDF file. Upon receipt, the author(s) must notify the editorial office of any errors found in the file within 48 hours. Any errors found after this time are the responsibility of the author(s) and will have to be corrected as an erratum.

4. Correction

To correct errors in published articles, the corresponding author should contact the journal’s editorial office with a detailed description of the proposed correction. Correc- tions that seriously affect the interpretation or conclusions of the article will be reviewed by the editors. Corrections will be published as an author correction or a publisher correction in a later issue of the journal.
Minor errors will be corrected directly in the online ver- sion of the article. An indication of the correction, along with the date it was made, will be added to the article infor- mation in both the HTML and PDF versions. A separate correction note will not be published.

VI. ARTICLE PROCESSING CHARGE

When a manuscript is accepted for publication, an article processing charge (APC) of 600 USD (KRW 600,000) per ar- ticle is charged to the corresponding author.

VII. COPYRIGHT, OPEN ACCESS POLICY

1. Copyright

All manuscripts published in KJAN are protected by copy- right. The copyright and transfer rights of the digital con- tent of the published paper and journal are owned by the

KSAN. Copyright Transfer Agreement form should be sub- mitted online at submission. All authors should print their names and sign the copyright transfer agreement.

2. Open Access Policy

KJAN is an open-access journal. Articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 (CC BY-NC-ND 4.0) li- cense, which permits copying and distributing the material in any medium or format in unadapted form only, for non- commercial purposes only, and only so long as attribution is given to the KJAN.

VIII. OTHER EDITORIAL POLICY

1. Archiving Policy

All manuscripts published in KJAN are freely available through open access to read and download from any elec- tronic link, including those found on the KJAN website (http://www.kjan.or.kr/) immediately and permanently af- ter publication.